You can buy or sell BioLineRx and other stocks, options, ETFs, and crypto commission-free!
BioLineRx Ltd. American Depositary Shares, also called BioLineRx, is a clinical-stage biopharmaceutical company, which includes indentifying, in-licensing, and developing therapeutic candidates. Read More Its in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, and develops them through pre-clinical and clinical stages, and then partners with pharmaceutical companies clinical development and commercialization. The company was founded in April 2003 and is headquartered in Modi'in, Israel.
Modi'in, Tel Aviv
52 Week High
52 Week Low
PR NewswireMar 14
BioLineRx to Present at the 29th Annual Oppenheimer Healthcare Conference
TEL AVIV, Israel, March 14, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Chief Executive Officer, Philip Serlin, will present a company update at the 29th Annual Oppenheimer Healthcare Conference on Tuesday, March 19, 2019 at 3:20 p.m. (EDT). The conference will be held at the Westin Grand Central Hotel in New York, NY. A live webcast of the presentation will be available on BioLineRx's website. A r...
Stock Price, News, & Analysis for BIOLINERX LTD/S
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. The company has collaboration agreement with Nov...
-$0.09 per share
Expected Mar 26, Pre-Market